Next Dr. Haas discussed CVB’s mission to advance brain health by advancing precision medicine solutions. Dr. Haas shared an update on the Brain Trauma Blueprint, a roadmap to advance a first generation of targeted solutions for TBI, focusing on the chronic sequelae. The Brain Trauma Blueprint is born from the recognition that there are currently no FDA-approved therapies for TBI, and was the basis for the 2019 State of the Science Summit on TBI, which brought together over 100 thought leaders across the research ecosystem to identify the research gaps that have stymied progress as well as specific recommendations to overcome these gaps through a consensus research roadmap. The specific recommendations are to be published as part of a six part publication series in the Journal of Neurotrauma. If these efforts to align resources toward these gaps and priorities is successful, it will help catalyze a first generation of targeted treatments for TBI. The Brain Trauma Blueprint has already led to new public-private partnerships and collaborations, many of which were described in this briefing. Dr. Haas outlined some of the most pressing needs identified through the Brain Trauma Blueprint, including the need for a national surveillance system for all severities of TBI. At this time, the United States does not have a reliable method for tracking TBI; rather, it only tracks individuals affected by TBI based on emergency room encounters. It is important that a national surveillance system to track the number of individuals who sustain TBI, including those who do not seek care in an emergency setting.